nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—RAF1—breast cancer	0.142	0.334	CbGaD
Dabrafenib—SLCO1B1—breast cancer	0.1	0.237	CbGaD
Dabrafenib—BRAF—breast cancer	0.0985	0.232	CbGaD
Dabrafenib—ABCG2—breast cancer	0.0437	0.103	CbGaD
Dabrafenib—CYP3A4—breast cancer	0.0219	0.0515	CbGaD
Dabrafenib—SLCO1B3—Paclitaxel—breast cancer	0.0193	0.0635	CbGbCtD
Dabrafenib—ABCB1—breast cancer	0.0182	0.0429	CbGaD
Dabrafenib—SLCO1B3—Docetaxel—breast cancer	0.014	0.0459	CbGbCtD
Dabrafenib—CYP2C8—Lapatinib—breast cancer	0.0122	0.0401	CbGbCtD
Dabrafenib—ABCG2—Tamoxifen—breast cancer	0.0115	0.0377	CbGbCtD
Dabrafenib—ABCB1—Toremifene—breast cancer	0.0113	0.0372	CbGbCtD
Dabrafenib—ABCG2—Mitoxantrone—breast cancer	0.0112	0.0368	CbGbCtD
Dabrafenib—SLCO1B1—Irinotecan—breast cancer	0.0111	0.0365	CbGbCtD
Dabrafenib—SLCO1B3—Methotrexate—breast cancer	0.0101	0.0331	CbGbCtD
Dabrafenib—CYP3A4—Exemestane—breast cancer	0.00979	0.0322	CbGbCtD
Dabrafenib—CYP2C8—Raloxifene—breast cancer	0.00925	0.0304	CbGbCtD
Dabrafenib—ABCG2—Paclitaxel—breast cancer	0.00893	0.0294	CbGbCtD
Dabrafenib—ABCG2—Irinotecan—breast cancer	0.00881	0.029	CbGbCtD
Dabrafenib—ABCG2—Fluorouracil—breast cancer	0.00845	0.0278	CbGbCtD
Dabrafenib—ABCG2—Carboplatin—breast cancer	0.0084	0.0276	CbGbCtD
Dabrafenib—CYP3A4—Letrozole—breast cancer	0.00832	0.0274	CbGbCtD
Dabrafenib—ABCB1—Lapatinib—breast cancer	0.00826	0.0272	CbGbCtD
Dabrafenib—CYP3A4—Anastrozole—breast cancer	0.00742	0.0244	CbGbCtD
Dabrafenib—CYP3A4—Toremifene—breast cancer	0.00679	0.0223	CbGbCtD
Dabrafenib—ABCG2—Docetaxel—breast cancer	0.00646	0.0212	CbGbCtD
Dabrafenib—CYP3A4—Fulvestrant—breast cancer	0.00631	0.0207	CbGbCtD
Dabrafenib—CYP2C8—Tamoxifen—breast cancer	0.00611	0.0201	CbGbCtD
Dabrafenib—SLCO1B1—Methotrexate—breast cancer	0.00587	0.0193	CbGbCtD
Dabrafenib—CYP3A4—Thiotepa—breast cancer	0.00562	0.0185	CbGbCtD
Dabrafenib—SLC22A8—Methotrexate—breast cancer	0.00542	0.0178	CbGbCtD
Dabrafenib—CYP3A4—Ixabepilone—breast cancer	0.00514	0.0169	CbGbCtD
Dabrafenib—CYP3A4—Lapatinib—breast cancer	0.00495	0.0163	CbGbCtD
Dabrafenib—ABCG2—Doxorubicin—breast cancer	0.00481	0.0158	CbGbCtD
Dabrafenib—CYP2C8—Paclitaxel—breast cancer	0.00476	0.0156	CbGbCtD
Dabrafenib—ABCG2—Methotrexate—breast cancer	0.00466	0.0153	CbGbCtD
Dabrafenib—ABCB1—Vinorelbine—breast cancer	0.00458	0.0151	CbGbCtD
Dabrafenib—CYP2C8—Fluorouracil—breast cancer	0.0045	0.0148	CbGbCtD
Dabrafenib—ABCB1—Tamoxifen—breast cancer	0.00414	0.0136	CbGbCtD
Dabrafenib—ABCB1—Mitoxantrone—breast cancer	0.00403	0.0133	CbGbCtD
Dabrafenib—SLC22A6—Methotrexate—breast cancer	0.00377	0.0124	CbGbCtD
Dabrafenib—CYP3A4—Raloxifene—breast cancer	0.00375	0.0123	CbGbCtD
Dabrafenib—ABCB1—Gemcitabine—breast cancer	0.00356	0.0117	CbGbCtD
Dabrafenib—ABCB1—Paclitaxel—breast cancer	0.00322	0.0106	CbGbCtD
Dabrafenib—ABCB1—Irinotecan—breast cancer	0.00318	0.0104	CbGbCtD
Dabrafenib—ABCB1—Vinblastine—breast cancer	0.00282	0.00929	CbGbCtD
Dabrafenib—CYP3A4—Vinorelbine—breast cancer	0.00275	0.00903	CbGbCtD
Dabrafenib—CYP3A4—Tamoxifen—breast cancer	0.00248	0.00815	CbGbCtD
Dabrafenib—CYP3A4—Mitoxantrone—breast cancer	0.00242	0.00795	CbGbCtD
Dabrafenib—ABCB1—Docetaxel—breast cancer	0.00233	0.00765	CbGbCtD
Dabrafenib—CYP3A4—Paclitaxel—breast cancer	0.00193	0.00634	CbGbCtD
Dabrafenib—CYP3A4—Irinotecan—breast cancer	0.0019	0.00626	CbGbCtD
Dabrafenib—RAF1—Topotecan—Irinotecan—breast cancer	0.00183	1	CbGdCrCtD
Dabrafenib—ABCB1—Doxorubicin—breast cancer	0.00174	0.00571	CbGbCtD
Dabrafenib—NEK11—uterus—breast cancer	0.00173	0.0462	CbGeAlD
Dabrafenib—CYP3A4—Vinblastine—breast cancer	0.00169	0.00556	CbGbCtD
Dabrafenib—ABCB1—Methotrexate—breast cancer	0.00168	0.00553	CbGbCtD
Dabrafenib—NEK11—female reproductive system—breast cancer	0.00156	0.0415	CbGeAlD
Dabrafenib—NEK11—adrenal gland—breast cancer	0.00152	0.0405	CbGeAlD
Dabrafenib—NEK11—female gonad—breast cancer	0.00142	0.0378	CbGeAlD
Dabrafenib—CYP3A4—Docetaxel—breast cancer	0.00139	0.00459	CbGbCtD
Dabrafenib—SIK1—mammary gland—breast cancer	0.00139	0.0372	CbGeAlD
Dabrafenib—LIMK1—adipose tissue—breast cancer	0.00121	0.0323	CbGeAlD
Dabrafenib—LIMK1—adrenal gland—breast cancer	0.00109	0.029	CbGeAlD
Dabrafenib—CYP3A4—Doxorubicin—breast cancer	0.00104	0.00342	CbGbCtD
Dabrafenib—RAF1—nipple—breast cancer	0.000917	0.0245	CbGeAlD
Dabrafenib—NEK11—lymph node—breast cancer	0.000911	0.0243	CbGeAlD
Dabrafenib—BRAF—endometrium—breast cancer	0.000831	0.0222	CbGeAlD
Dabrafenib—SLCO1B1—mammary gland—breast cancer	0.000829	0.0221	CbGeAlD
Dabrafenib—BRAF—uterus—breast cancer	0.000766	0.0204	CbGeAlD
Dabrafenib—RAF1—embryo—breast cancer	0.000757	0.0202	CbGeAlD
Dabrafenib—BRAF—pituitary gland—breast cancer	0.000752	0.0201	CbGeAlD
Dabrafenib—BRAF—adipose tissue—breast cancer	0.000749	0.02	CbGeAlD
Dabrafenib—SIK1—skin of body—breast cancer	0.000738	0.0197	CbGeAlD
Dabrafenib—SIK1—endometrium—breast cancer	0.000695	0.0186	CbGeAlD
Dabrafenib—BRAF—adrenal gland—breast cancer	0.000672	0.0179	CbGeAlD
Dabrafenib—LIMK1—lymph node—breast cancer	0.000652	0.0174	CbGeAlD
Dabrafenib—BRAF—bone marrow—breast cancer	0.00065	0.0173	CbGeAlD
Dabrafenib—SLCO1B3—pituitary gland—breast cancer	0.000648	0.0173	CbGeAlD
Dabrafenib—SIK1—uterus—breast cancer	0.000641	0.0171	CbGeAlD
Dabrafenib—SIK1—pituitary gland—breast cancer	0.000629	0.0168	CbGeAlD
Dabrafenib—SIK1—adipose tissue—breast cancer	0.000627	0.0167	CbGeAlD
Dabrafenib—BRAF—female gonad—breast cancer	0.000626	0.0167	CbGeAlD
Dabrafenib—RAF1—epithelium—breast cancer	0.000617	0.0165	CbGeAlD
Dabrafenib—RAF1—skin of body—breast cancer	0.000587	0.0157	CbGeAlD
Dabrafenib—SIK1—female reproductive system—breast cancer	0.000576	0.0154	CbGeAlD
Dabrafenib—SIK1—adrenal gland—breast cancer	0.000562	0.015	CbGeAlD
Dabrafenib—RAF1—endometrium—breast cancer	0.000554	0.0148	CbGeAlD
Dabrafenib—SIK1—bone marrow—breast cancer	0.000544	0.0145	CbGeAlD
Dabrafenib—SIK1—female gonad—breast cancer	0.000524	0.014	CbGeAlD
Dabrafenib—RAF1—uterus—breast cancer	0.00051	0.0136	CbGeAlD
Dabrafenib—SLCO1B3—endocrine gland—breast cancer	0.000502	0.0134	CbGeAlD
Dabrafenib—RAF1—pituitary gland—breast cancer	0.000501	0.0134	CbGeAlD
Dabrafenib—RAF1—adipose tissue—breast cancer	0.000499	0.0133	CbGeAlD
Dabrafenib—SIK1—endocrine gland—breast cancer	0.000488	0.013	CbGeAlD
Dabrafenib—CYP2C8—mammary gland—breast cancer	0.000472	0.0126	CbGeAlD
Dabrafenib—RAF1—female reproductive system—breast cancer	0.000459	0.0122	CbGeAlD
Dabrafenib—RAF1—adrenal gland—breast cancer	0.000448	0.0119	CbGeAlD
Dabrafenib—RAF1—bone marrow—breast cancer	0.000433	0.0116	CbGeAlD
Dabrafenib—RAF1—female gonad—breast cancer	0.000417	0.0111	CbGeAlD
Dabrafenib—BRAF—lymph node—breast cancer	0.000403	0.0107	CbGeAlD
Dabrafenib—RAF1—endocrine gland—breast cancer	0.000388	0.0104	CbGeAlD
Dabrafenib—SLCO1B1—female reproductive system—breast cancer	0.000343	0.00916	CbGeAlD
Dabrafenib—SIK1—lymph node—breast cancer	0.000337	0.00899	CbGeAlD
Dabrafenib—SLCO1B1—endocrine gland—breast cancer	0.00029	0.00775	CbGeAlD
Dabrafenib—RAF1—lymph node—breast cancer	0.000268	0.00716	CbGeAlD
Dabrafenib—CYP2C8—endometrium—breast cancer	0.000236	0.00628	CbGeAlD
Dabrafenib—ABCG2—endometrium—breast cancer	0.000229	0.00611	CbGeAlD
Dabrafenib—CYP2C8—pituitary gland—breast cancer	0.000213	0.00569	CbGeAlD
Dabrafenib—ABCG2—uterus—breast cancer	0.000211	0.00563	CbGeAlD
Dabrafenib—ABCG2—pituitary gland—breast cancer	0.000207	0.00553	CbGeAlD
Dabrafenib—ABCG2—adipose tissue—breast cancer	0.000206	0.00551	CbGeAlD
Dabrafenib—CYP2C8—female reproductive system—breast cancer	0.000195	0.00521	CbGeAlD
Dabrafenib—ABCG2—adrenal gland—breast cancer	0.000185	0.00494	CbGeAlD
Dabrafenib—ABCG2—bone marrow—breast cancer	0.000179	0.00478	CbGeAlD
Dabrafenib—ABCG2—female gonad—breast cancer	0.000173	0.00461	CbGeAlD
Dabrafenib—CYP2C8—endocrine gland—breast cancer	0.000165	0.00441	CbGeAlD
Dabrafenib—ABCB1—embryo—breast cancer	0.000154	0.00412	CbGeAlD
Dabrafenib—CYP3A4—female reproductive system—breast cancer	0.000132	0.00353	CbGeAlD
Dabrafenib—ABCB1—epithelium—breast cancer	0.000126	0.00336	CbGeAlD
Dabrafenib—ABCB1—endometrium—breast cancer	0.000113	0.00301	CbGeAlD
Dabrafenib—CYP3A4—endocrine gland—breast cancer	0.000112	0.00298	CbGeAlD
Dabrafenib—ABCG2—lymph node—breast cancer	0.000111	0.00296	CbGeAlD
Dabrafenib—ABCB1—uterus—breast cancer	0.000104	0.00278	CbGeAlD
Dabrafenib—ABCB1—pituitary gland—breast cancer	0.000102	0.00273	CbGeAlD
Dabrafenib—ABCB1—adipose tissue—breast cancer	0.000102	0.00272	CbGeAlD
Dabrafenib—ABCB1—female reproductive system—breast cancer	9.35e-05	0.0025	CbGeAlD
Dabrafenib—ABCB1—adrenal gland—breast cancer	9.13e-05	0.00244	CbGeAlD
Dabrafenib—ABCB1—bone marrow—breast cancer	8.83e-05	0.00236	CbGeAlD
Dabrafenib—ABCB1—female gonad—breast cancer	8.51e-05	0.00227	CbGeAlD
Dabrafenib—ABCB1—endocrine gland—breast cancer	7.92e-05	0.00211	CbGeAlD
Dabrafenib—ABCB1—lymph node—breast cancer	5.47e-05	0.00146	CbGeAlD
Dabrafenib—Epistaxis—Epirubicin—breast cancer	2.59e-05	0.0002	CcSEcCtD
Dabrafenib—Pruritus—Gemcitabine—breast cancer	2.59e-05	0.0002	CcSEcCtD
Dabrafenib—Nausea—Thiotepa—breast cancer	2.58e-05	0.0002	CcSEcCtD
Dabrafenib—Urethral disorder—Methotrexate—breast cancer	2.58e-05	0.000199	CcSEcCtD
Dabrafenib—Infection—Docetaxel—breast cancer	2.58e-05	0.000199	CcSEcCtD
Dabrafenib—Hyperglycaemia—Doxorubicin—breast cancer	2.57e-05	0.000199	CcSEcCtD
Dabrafenib—Diarrhoea—Mitoxantrone—breast cancer	2.57e-05	0.000199	CcSEcCtD
Dabrafenib—Diarrhoea—Irinotecan—breast cancer	2.57e-05	0.000199	CcSEcCtD
Dabrafenib—Dry mouth—Capecitabine—breast cancer	2.56e-05	0.000198	CcSEcCtD
Dabrafenib—Nervous system disorder—Docetaxel—breast cancer	2.54e-05	0.000197	CcSEcCtD
Dabrafenib—Pruritus—Fluorouracil—breast cancer	2.54e-05	0.000197	CcSEcCtD
Dabrafenib—Thrombocytopenia—Docetaxel—breast cancer	2.54e-05	0.000196	CcSEcCtD
Dabrafenib—Infestation—Doxorubicin—breast cancer	2.54e-05	0.000196	CcSEcCtD
Dabrafenib—Infestation NOS—Doxorubicin—breast cancer	2.54e-05	0.000196	CcSEcCtD
Dabrafenib—Skin disorder—Docetaxel—breast cancer	2.52e-05	0.000195	CcSEcCtD
Dabrafenib—Oedema—Capecitabine—breast cancer	2.51e-05	0.000194	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Paclitaxel—breast cancer	2.5e-05	0.000194	CcSEcCtD
Dabrafenib—Diarrhoea—Gemcitabine—breast cancer	2.5e-05	0.000193	CcSEcCtD
Dabrafenib—Renal failure—Doxorubicin—breast cancer	2.5e-05	0.000193	CcSEcCtD
Dabrafenib—Infection—Capecitabine—breast cancer	2.5e-05	0.000193	CcSEcCtD
Dabrafenib—Dizziness—Irinotecan—breast cancer	2.48e-05	0.000192	CcSEcCtD
Dabrafenib—Haemoglobin—Epirubicin—breast cancer	2.48e-05	0.000191	CcSEcCtD
Dabrafenib—Stomatitis—Doxorubicin—breast cancer	2.47e-05	0.000191	CcSEcCtD
Dabrafenib—Urinary tract infection—Doxorubicin—breast cancer	2.47e-05	0.000191	CcSEcCtD
Dabrafenib—Nervous system disorder—Capecitabine—breast cancer	2.46e-05	0.00019	CcSEcCtD
Dabrafenib—Haemorrhage—Epirubicin—breast cancer	2.46e-05	0.00019	CcSEcCtD
Dabrafenib—Eye disorder—Methotrexate—breast cancer	2.46e-05	0.00019	CcSEcCtD
Dabrafenib—Diarrhoea—Fluorouracil—breast cancer	2.46e-05	0.00019	CcSEcCtD
Dabrafenib—Thrombocytopenia—Capecitabine—breast cancer	2.46e-05	0.00019	CcSEcCtD
Dabrafenib—Skin disorder—Capecitabine—breast cancer	2.44e-05	0.000189	CcSEcCtD
Dabrafenib—Urinary tract disorder—Epirubicin—breast cancer	2.43e-05	0.000188	CcSEcCtD
Dabrafenib—Hyperhidrosis—Capecitabine—breast cancer	2.43e-05	0.000188	CcSEcCtD
Dabrafenib—Oedema peripheral—Epirubicin—breast cancer	2.43e-05	0.000188	CcSEcCtD
Dabrafenib—Hypotension—Docetaxel—breast cancer	2.42e-05	0.000187	CcSEcCtD
Dabrafenib—Haematuria—Doxorubicin—breast cancer	2.42e-05	0.000187	CcSEcCtD
Dabrafenib—Connective tissue disorder—Epirubicin—breast cancer	2.42e-05	0.000187	CcSEcCtD
Dabrafenib—Abdominal pain—Paclitaxel—breast cancer	2.42e-05	0.000187	CcSEcCtD
Dabrafenib—Body temperature increased—Paclitaxel—breast cancer	2.42e-05	0.000187	CcSEcCtD
Dabrafenib—Urethral disorder—Epirubicin—breast cancer	2.41e-05	0.000187	CcSEcCtD
Dabrafenib—Epistaxis—Doxorubicin—breast cancer	2.39e-05	0.000185	CcSEcCtD
Dabrafenib—Angiopathy—Methotrexate—breast cancer	2.39e-05	0.000185	CcSEcCtD
Dabrafenib—Vomiting—Irinotecan—breast cancer	2.39e-05	0.000185	CcSEcCtD
Dabrafenib—Vomiting—Mitoxantrone—breast cancer	2.39e-05	0.000185	CcSEcCtD
Dabrafenib—Immune system disorder—Methotrexate—breast cancer	2.38e-05	0.000184	CcSEcCtD
Dabrafenib—Dizziness—Fluorouracil—breast cancer	2.38e-05	0.000184	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methotrexate—breast cancer	2.37e-05	0.000183	CcSEcCtD
Dabrafenib—Rash—Irinotecan—breast cancer	2.37e-05	0.000183	CcSEcCtD
Dabrafenib—Rash—Mitoxantrone—breast cancer	2.37e-05	0.000183	CcSEcCtD
Dabrafenib—Dermatitis—Mitoxantrone—breast cancer	2.36e-05	0.000183	CcSEcCtD
Dabrafenib—Dermatitis—Irinotecan—breast cancer	2.36e-05	0.000183	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Docetaxel—breast cancer	2.36e-05	0.000183	CcSEcCtD
Dabrafenib—Chills—Methotrexate—breast cancer	2.36e-05	0.000183	CcSEcCtD
Dabrafenib—Headache—Mitoxantrone—breast cancer	2.35e-05	0.000182	CcSEcCtD
Dabrafenib—Headache—Irinotecan—breast cancer	2.35e-05	0.000182	CcSEcCtD
Dabrafenib—Hypotension—Capecitabine—breast cancer	2.35e-05	0.000181	CcSEcCtD
Dabrafenib—Insomnia—Docetaxel—breast cancer	2.35e-05	0.000181	CcSEcCtD
Dabrafenib—Alopecia—Methotrexate—breast cancer	2.33e-05	0.00018	CcSEcCtD
Dabrafenib—Vomiting—Gemcitabine—breast cancer	2.32e-05	0.00018	CcSEcCtD
Dabrafenib—Mental disorder—Methotrexate—breast cancer	2.31e-05	0.000178	CcSEcCtD
Dabrafenib—Rash—Gemcitabine—breast cancer	2.3e-05	0.000178	CcSEcCtD
Dabrafenib—Dermatitis—Gemcitabine—breast cancer	2.3e-05	0.000178	CcSEcCtD
Dabrafenib—Eye disorder—Epirubicin—breast cancer	2.3e-05	0.000178	CcSEcCtD
Dabrafenib—Erythema—Methotrexate—breast cancer	2.29e-05	0.000177	CcSEcCtD
Dabrafenib—Malnutrition—Methotrexate—breast cancer	2.29e-05	0.000177	CcSEcCtD
Dabrafenib—Haemoglobin—Doxorubicin—breast cancer	2.29e-05	0.000177	CcSEcCtD
Dabrafenib—Headache—Gemcitabine—breast cancer	2.29e-05	0.000177	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Capecitabine—breast cancer	2.29e-05	0.000177	CcSEcCtD
Dabrafenib—Vomiting—Fluorouracil—breast cancer	2.29e-05	0.000177	CcSEcCtD
Dabrafenib—Haemorrhage—Doxorubicin—breast cancer	2.28e-05	0.000176	CcSEcCtD
Dabrafenib—Insomnia—Capecitabine—breast cancer	2.27e-05	0.000176	CcSEcCtD
Dabrafenib—Rash—Fluorouracil—breast cancer	2.27e-05	0.000175	CcSEcCtD
Dabrafenib—Dermatitis—Fluorouracil—breast cancer	2.26e-05	0.000175	CcSEcCtD
Dabrafenib—Decreased appetite—Docetaxel—breast cancer	2.26e-05	0.000174	CcSEcCtD
Dabrafenib—Hypersensitivity—Paclitaxel—breast cancer	2.25e-05	0.000174	CcSEcCtD
Dabrafenib—Headache—Fluorouracil—breast cancer	2.25e-05	0.000174	CcSEcCtD
Dabrafenib—Urinary tract disorder—Doxorubicin—breast cancer	2.25e-05	0.000174	CcSEcCtD
Dabrafenib—Oedema peripheral—Doxorubicin—breast cancer	2.24e-05	0.000174	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Docetaxel—breast cancer	2.24e-05	0.000173	CcSEcCtD
Dabrafenib—Connective tissue disorder—Doxorubicin—breast cancer	2.24e-05	0.000173	CcSEcCtD
Dabrafenib—Fatigue—Docetaxel—breast cancer	2.24e-05	0.000173	CcSEcCtD
Dabrafenib—Angiopathy—Epirubicin—breast cancer	2.23e-05	0.000173	CcSEcCtD
Dabrafenib—Urethral disorder—Doxorubicin—breast cancer	2.23e-05	0.000173	CcSEcCtD
Dabrafenib—Nausea—Irinotecan—breast cancer	2.23e-05	0.000172	CcSEcCtD
Dabrafenib—Nausea—Mitoxantrone—breast cancer	2.23e-05	0.000172	CcSEcCtD
Dabrafenib—Immune system disorder—Epirubicin—breast cancer	2.22e-05	0.000172	CcSEcCtD
Dabrafenib—Mediastinal disorder—Epirubicin—breast cancer	2.22e-05	0.000172	CcSEcCtD
Dabrafenib—Constipation—Docetaxel—breast cancer	2.22e-05	0.000172	CcSEcCtD
Dabrafenib—Back pain—Methotrexate—breast cancer	2.22e-05	0.000171	CcSEcCtD
Dabrafenib—Chills—Epirubicin—breast cancer	2.21e-05	0.000171	CcSEcCtD
Dabrafenib—Arrhythmia—Epirubicin—breast cancer	2.2e-05	0.00017	CcSEcCtD
Dabrafenib—Asthenia—Paclitaxel—breast cancer	2.2e-05	0.00017	CcSEcCtD
Dabrafenib—Decreased appetite—Capecitabine—breast cancer	2.18e-05	0.000169	CcSEcCtD
Dabrafenib—Alopecia—Epirubicin—breast cancer	2.18e-05	0.000168	CcSEcCtD
Dabrafenib—Nausea—Gemcitabine—breast cancer	2.17e-05	0.000168	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Capecitabine—breast cancer	2.17e-05	0.000168	CcSEcCtD
Dabrafenib—Fatigue—Capecitabine—breast cancer	2.17e-05	0.000167	CcSEcCtD
Dabrafenib—Pruritus—Paclitaxel—breast cancer	2.17e-05	0.000167	CcSEcCtD
Dabrafenib—Vision blurred—Methotrexate—breast cancer	2.16e-05	0.000167	CcSEcCtD
Dabrafenib—Mental disorder—Epirubicin—breast cancer	2.16e-05	0.000167	CcSEcCtD
Dabrafenib—Constipation—Capecitabine—breast cancer	2.15e-05	0.000166	CcSEcCtD
Dabrafenib—Malnutrition—Epirubicin—breast cancer	2.14e-05	0.000166	CcSEcCtD
Dabrafenib—Erythema—Epirubicin—breast cancer	2.14e-05	0.000166	CcSEcCtD
Dabrafenib—Nausea—Fluorouracil—breast cancer	2.13e-05	0.000165	CcSEcCtD
Dabrafenib—Eye disorder—Doxorubicin—breast cancer	2.13e-05	0.000165	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Docetaxel—breast cancer	2.12e-05	0.000164	CcSEcCtD
Dabrafenib—Anaemia—Methotrexate—breast cancer	2.12e-05	0.000164	CcSEcCtD
Dabrafenib—Diarrhoea—Paclitaxel—breast cancer	2.09e-05	0.000162	CcSEcCtD
Dabrafenib—Back pain—Epirubicin—breast cancer	2.07e-05	0.00016	CcSEcCtD
Dabrafenib—Angiopathy—Doxorubicin—breast cancer	2.07e-05	0.00016	CcSEcCtD
Dabrafenib—Muscle spasms—Epirubicin—breast cancer	2.06e-05	0.000159	CcSEcCtD
Dabrafenib—Immune system disorder—Doxorubicin—breast cancer	2.06e-05	0.000159	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Capecitabine—breast cancer	2.05e-05	0.000159	CcSEcCtD
Dabrafenib—Mediastinal disorder—Doxorubicin—breast cancer	2.05e-05	0.000159	CcSEcCtD
Dabrafenib—Abdominal pain—Docetaxel—breast cancer	2.05e-05	0.000159	CcSEcCtD
Dabrafenib—Body temperature increased—Docetaxel—breast cancer	2.05e-05	0.000159	CcSEcCtD
Dabrafenib—Leukopenia—Methotrexate—breast cancer	2.05e-05	0.000159	CcSEcCtD
Dabrafenib—Chills—Doxorubicin—breast cancer	2.04e-05	0.000158	CcSEcCtD
Dabrafenib—Arrhythmia—Doxorubicin—breast cancer	2.04e-05	0.000157	CcSEcCtD
Dabrafenib—Dizziness—Paclitaxel—breast cancer	2.02e-05	0.000157	CcSEcCtD
Dabrafenib—Vision blurred—Epirubicin—breast cancer	2.02e-05	0.000156	CcSEcCtD
Dabrafenib—Alopecia—Doxorubicin—breast cancer	2.01e-05	0.000156	CcSEcCtD
Dabrafenib—Cough—Methotrexate—breast cancer	2e-05	0.000155	CcSEcCtD
Dabrafenib—Mental disorder—Doxorubicin—breast cancer	2e-05	0.000154	CcSEcCtD
Dabrafenib—Body temperature increased—Capecitabine—breast cancer	1.99e-05	0.000154	CcSEcCtD
Dabrafenib—Abdominal pain—Capecitabine—breast cancer	1.99e-05	0.000154	CcSEcCtD
Dabrafenib—Erythema—Doxorubicin—breast cancer	1.98e-05	0.000153	CcSEcCtD
Dabrafenib—Malnutrition—Doxorubicin—breast cancer	1.98e-05	0.000153	CcSEcCtD
Dabrafenib—Anaemia—Epirubicin—breast cancer	1.98e-05	0.000153	CcSEcCtD
Dabrafenib—Myalgia—Methotrexate—breast cancer	1.95e-05	0.000151	CcSEcCtD
Dabrafenib—Arthralgia—Methotrexate—breast cancer	1.95e-05	0.000151	CcSEcCtD
Dabrafenib—Vomiting—Paclitaxel—breast cancer	1.95e-05	0.00015	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.94e-05	0.00015	CcSEcCtD
Dabrafenib—Rash—Paclitaxel—breast cancer	1.93e-05	0.000149	CcSEcCtD
Dabrafenib—Dermatitis—Paclitaxel—breast cancer	1.93e-05	0.000149	CcSEcCtD
Dabrafenib—Leukopenia—Epirubicin—breast cancer	1.92e-05	0.000148	CcSEcCtD
Dabrafenib—Back pain—Doxorubicin—breast cancer	1.92e-05	0.000148	CcSEcCtD
Dabrafenib—Headache—Paclitaxel—breast cancer	1.92e-05	0.000148	CcSEcCtD
Dabrafenib—Hypersensitivity—Docetaxel—breast cancer	1.91e-05	0.000148	CcSEcCtD
Dabrafenib—Muscle spasms—Doxorubicin—breast cancer	1.91e-05	0.000147	CcSEcCtD
Dabrafenib—Cough—Epirubicin—breast cancer	1.87e-05	0.000145	CcSEcCtD
Dabrafenib—Vision blurred—Doxorubicin—breast cancer	1.87e-05	0.000145	CcSEcCtD
Dabrafenib—Asthenia—Docetaxel—breast cancer	1.86e-05	0.000144	CcSEcCtD
Dabrafenib—Infection—Methotrexate—breast cancer	1.86e-05	0.000144	CcSEcCtD
Dabrafenib—Hypertension—Epirubicin—breast cancer	1.85e-05	0.000143	CcSEcCtD
Dabrafenib—Hypersensitivity—Capecitabine—breast cancer	1.85e-05	0.000143	CcSEcCtD
Dabrafenib—Pruritus—Docetaxel—breast cancer	1.84e-05	0.000142	CcSEcCtD
Dabrafenib—Nervous system disorder—Methotrexate—breast cancer	1.83e-05	0.000142	CcSEcCtD
Dabrafenib—Anaemia—Doxorubicin—breast cancer	1.83e-05	0.000142	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methotrexate—breast cancer	1.83e-05	0.000142	CcSEcCtD
Dabrafenib—Arthralgia—Epirubicin—breast cancer	1.83e-05	0.000141	CcSEcCtD
Dabrafenib—Myalgia—Epirubicin—breast cancer	1.83e-05	0.000141	CcSEcCtD
Dabrafenib—Nausea—Paclitaxel—breast cancer	1.82e-05	0.000141	CcSEcCtD
Dabrafenib—Skin disorder—Methotrexate—breast cancer	1.82e-05	0.00014	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.81e-05	0.00014	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methotrexate—breast cancer	1.81e-05	0.00014	CcSEcCtD
Dabrafenib—Asthenia—Capecitabine—breast cancer	1.8e-05	0.000139	CcSEcCtD
Dabrafenib—Dry mouth—Epirubicin—breast cancer	1.79e-05	0.000138	CcSEcCtD
Dabrafenib—Pruritus—Capecitabine—breast cancer	1.78e-05	0.000137	CcSEcCtD
Dabrafenib—Leukopenia—Doxorubicin—breast cancer	1.78e-05	0.000137	CcSEcCtD
Dabrafenib—Diarrhoea—Docetaxel—breast cancer	1.77e-05	0.000137	CcSEcCtD
Dabrafenib—Oedema—Epirubicin—breast cancer	1.75e-05	0.000135	CcSEcCtD
Dabrafenib—Hypotension—Methotrexate—breast cancer	1.75e-05	0.000135	CcSEcCtD
Dabrafenib—Infection—Epirubicin—breast cancer	1.74e-05	0.000134	CcSEcCtD
Dabrafenib—Cough—Doxorubicin—breast cancer	1.73e-05	0.000134	CcSEcCtD
Dabrafenib—Diarrhoea—Capecitabine—breast cancer	1.72e-05	0.000133	CcSEcCtD
Dabrafenib—Nervous system disorder—Epirubicin—breast cancer	1.72e-05	0.000133	CcSEcCtD
Dabrafenib—Dizziness—Docetaxel—breast cancer	1.72e-05	0.000133	CcSEcCtD
Dabrafenib—Thrombocytopenia—Epirubicin—breast cancer	1.71e-05	0.000132	CcSEcCtD
Dabrafenib—Hypertension—Doxorubicin—breast cancer	1.71e-05	0.000132	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methotrexate—breast cancer	1.7e-05	0.000132	CcSEcCtD
Dabrafenib—Skin disorder—Epirubicin—breast cancer	1.7e-05	0.000131	CcSEcCtD
Dabrafenib—Hyperhidrosis—Epirubicin—breast cancer	1.69e-05	0.000131	CcSEcCtD
Dabrafenib—Insomnia—Methotrexate—breast cancer	1.69e-05	0.000131	CcSEcCtD
Dabrafenib—Arthralgia—Doxorubicin—breast cancer	1.69e-05	0.000131	CcSEcCtD
Dabrafenib—Myalgia—Doxorubicin—breast cancer	1.69e-05	0.000131	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.68e-05	0.00013	CcSEcCtD
Dabrafenib—Dizziness—Capecitabine—breast cancer	1.66e-05	0.000128	CcSEcCtD
Dabrafenib—Dry mouth—Doxorubicin—breast cancer	1.65e-05	0.000128	CcSEcCtD
Dabrafenib—Vomiting—Docetaxel—breast cancer	1.65e-05	0.000128	CcSEcCtD
Dabrafenib—Rash—Docetaxel—breast cancer	1.64e-05	0.000126	CcSEcCtD
Dabrafenib—Hypotension—Epirubicin—breast cancer	1.64e-05	0.000126	CcSEcCtD
Dabrafenib—Dermatitis—Docetaxel—breast cancer	1.63e-05	0.000126	CcSEcCtD
Dabrafenib—Decreased appetite—Methotrexate—breast cancer	1.63e-05	0.000126	CcSEcCtD
Dabrafenib—Headache—Docetaxel—breast cancer	1.63e-05	0.000126	CcSEcCtD
Dabrafenib—Oedema—Doxorubicin—breast cancer	1.62e-05	0.000125	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Methotrexate—breast cancer	1.61e-05	0.000125	CcSEcCtD
Dabrafenib—Fatigue—Methotrexate—breast cancer	1.61e-05	0.000125	CcSEcCtD
Dabrafenib—Infection—Doxorubicin—breast cancer	1.61e-05	0.000124	CcSEcCtD
Dabrafenib—Vomiting—Capecitabine—breast cancer	1.6e-05	0.000123	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Epirubicin—breast cancer	1.59e-05	0.000123	CcSEcCtD
Dabrafenib—Nervous system disorder—Doxorubicin—breast cancer	1.59e-05	0.000123	CcSEcCtD
Dabrafenib—Thrombocytopenia—Doxorubicin—breast cancer	1.59e-05	0.000123	CcSEcCtD
Dabrafenib—Rash—Capecitabine—breast cancer	1.58e-05	0.000122	CcSEcCtD
Dabrafenib—Insomnia—Epirubicin—breast cancer	1.58e-05	0.000122	CcSEcCtD
Dabrafenib—Dermatitis—Capecitabine—breast cancer	1.58e-05	0.000122	CcSEcCtD
Dabrafenib—Headache—Capecitabine—breast cancer	1.57e-05	0.000122	CcSEcCtD
Dabrafenib—Skin disorder—Doxorubicin—breast cancer	1.57e-05	0.000122	CcSEcCtD
Dabrafenib—Hyperhidrosis—Doxorubicin—breast cancer	1.57e-05	0.000121	CcSEcCtD
Dabrafenib—Nausea—Docetaxel—breast cancer	1.54e-05	0.000119	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methotrexate—breast cancer	1.53e-05	0.000118	CcSEcCtD
Dabrafenib—Decreased appetite—Epirubicin—breast cancer	1.52e-05	0.000118	CcSEcCtD
Dabrafenib—Hypotension—Doxorubicin—breast cancer	1.51e-05	0.000117	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Epirubicin—breast cancer	1.51e-05	0.000117	CcSEcCtD
Dabrafenib—Fatigue—Epirubicin—breast cancer	1.51e-05	0.000117	CcSEcCtD
Dabrafenib—Constipation—Epirubicin—breast cancer	1.5e-05	0.000116	CcSEcCtD
Dabrafenib—Nausea—Capecitabine—breast cancer	1.49e-05	0.000115	CcSEcCtD
Dabrafenib—Abdominal pain—Methotrexate—breast cancer	1.48e-05	0.000114	CcSEcCtD
Dabrafenib—Body temperature increased—Methotrexate—breast cancer	1.48e-05	0.000114	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.48e-05	0.000114	CcSEcCtD
Dabrafenib—Insomnia—Doxorubicin—breast cancer	1.46e-05	0.000113	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Epirubicin—breast cancer	1.43e-05	0.000111	CcSEcCtD
Dabrafenib—Decreased appetite—Doxorubicin—breast cancer	1.41e-05	0.000109	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Doxorubicin—breast cancer	1.4e-05	0.000108	CcSEcCtD
Dabrafenib—Fatigue—Doxorubicin—breast cancer	1.4e-05	0.000108	CcSEcCtD
Dabrafenib—Constipation—Doxorubicin—breast cancer	1.38e-05	0.000107	CcSEcCtD
Dabrafenib—Abdominal pain—Epirubicin—breast cancer	1.38e-05	0.000107	CcSEcCtD
Dabrafenib—Body temperature increased—Epirubicin—breast cancer	1.38e-05	0.000107	CcSEcCtD
Dabrafenib—Hypersensitivity—Methotrexate—breast cancer	1.38e-05	0.000107	CcSEcCtD
Dabrafenib—Asthenia—Methotrexate—breast cancer	1.34e-05	0.000104	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Doxorubicin—breast cancer	1.32e-05	0.000102	CcSEcCtD
Dabrafenib—Pruritus—Methotrexate—breast cancer	1.32e-05	0.000102	CcSEcCtD
Dabrafenib—Hypersensitivity—Epirubicin—breast cancer	1.29e-05	9.97e-05	CcSEcCtD
Dabrafenib—Abdominal pain—Doxorubicin—breast cancer	1.28e-05	9.9e-05	CcSEcCtD
Dabrafenib—Body temperature increased—Doxorubicin—breast cancer	1.28e-05	9.9e-05	CcSEcCtD
Dabrafenib—Diarrhoea—Methotrexate—breast cancer	1.28e-05	9.89e-05	CcSEcCtD
Dabrafenib—Asthenia—Epirubicin—breast cancer	1.26e-05	9.71e-05	CcSEcCtD
Dabrafenib—Pruritus—Epirubicin—breast cancer	1.24e-05	9.57e-05	CcSEcCtD
Dabrafenib—Dizziness—Methotrexate—breast cancer	1.24e-05	9.56e-05	CcSEcCtD
Dabrafenib—Diarrhoea—Epirubicin—breast cancer	1.2e-05	9.26e-05	CcSEcCtD
Dabrafenib—Hypersensitivity—Doxorubicin—breast cancer	1.19e-05	9.22e-05	CcSEcCtD
Dabrafenib—Vomiting—Methotrexate—breast cancer	1.19e-05	9.19e-05	CcSEcCtD
Dabrafenib—Rash—Methotrexate—breast cancer	1.18e-05	9.12e-05	CcSEcCtD
Dabrafenib—Dermatitis—Methotrexate—breast cancer	1.18e-05	9.11e-05	CcSEcCtD
Dabrafenib—Headache—Methotrexate—breast cancer	1.17e-05	9.06e-05	CcSEcCtD
Dabrafenib—Asthenia—Doxorubicin—breast cancer	1.16e-05	8.98e-05	CcSEcCtD
Dabrafenib—Dizziness—Epirubicin—breast cancer	1.16e-05	8.95e-05	CcSEcCtD
Dabrafenib—Pruritus—Doxorubicin—breast cancer	1.15e-05	8.86e-05	CcSEcCtD
Dabrafenib—Vomiting—Epirubicin—breast cancer	1.11e-05	8.6e-05	CcSEcCtD
Dabrafenib—Nausea—Methotrexate—breast cancer	1.11e-05	8.59e-05	CcSEcCtD
Dabrafenib—Diarrhoea—Doxorubicin—breast cancer	1.11e-05	8.57e-05	CcSEcCtD
Dabrafenib—Rash—Epirubicin—breast cancer	1.1e-05	8.53e-05	CcSEcCtD
Dabrafenib—Dermatitis—Epirubicin—breast cancer	1.1e-05	8.52e-05	CcSEcCtD
Dabrafenib—Headache—Epirubicin—breast cancer	1.1e-05	8.48e-05	CcSEcCtD
Dabrafenib—Dizziness—Doxorubicin—breast cancer	1.07e-05	8.28e-05	CcSEcCtD
Dabrafenib—Nausea—Epirubicin—breast cancer	1.04e-05	8.04e-05	CcSEcCtD
Dabrafenib—Vomiting—Doxorubicin—breast cancer	1.03e-05	7.96e-05	CcSEcCtD
Dabrafenib—Rash—Doxorubicin—breast cancer	1.02e-05	7.89e-05	CcSEcCtD
Dabrafenib—Dermatitis—Doxorubicin—breast cancer	1.02e-05	7.89e-05	CcSEcCtD
Dabrafenib—Headache—Doxorubicin—breast cancer	1.01e-05	7.84e-05	CcSEcCtD
Dabrafenib—Nausea—Doxorubicin—breast cancer	9.62e-06	7.44e-05	CcSEcCtD
Dabrafenib—RAF1—Immune System—JUN—breast cancer	1.46e-06	1.43e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ESR1—breast cancer	1.46e-06	1.43e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CTNNB1—breast cancer	1.45e-06	1.42e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KRAS—breast cancer	1.45e-06	1.42e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—breast cancer	1.44e-06	1.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FN1—breast cancer	1.44e-06	1.41e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—FASN—breast cancer	1.44e-06	1.41e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CG—breast cancer	1.44e-06	1.41e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NCOA1—breast cancer	1.44e-06	1.4e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1B—breast cancer	1.43e-06	1.4e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—BCHE—breast cancer	1.43e-06	1.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NFKBIA—breast cancer	1.43e-06	1.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1B—breast cancer	1.42e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1A—breast cancer	1.42e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC5A5—breast cancer	1.42e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—STK11—breast cancer	1.42e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP19A1—breast cancer	1.42e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTEN—breast cancer	1.41e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOTCH1—breast cancer	1.41e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTA4—breast cancer	1.41e-06	1.37e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CA9—breast cancer	1.41e-06	1.37e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—breast cancer	1.41e-06	1.37e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—breast cancer	1.4e-06	1.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—breast cancer	1.4e-06	1.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK8—breast cancer	1.38e-06	1.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KIT—breast cancer	1.38e-06	1.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CG—breast cancer	1.38e-06	1.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APC—breast cancer	1.38e-06	1.35e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTA2—breast cancer	1.37e-06	1.34e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPX2—breast cancer	1.37e-06	1.34e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCND1—breast cancer	1.37e-06	1.34e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NQO1—breast cancer	1.37e-06	1.34e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC2A1—breast cancer	1.37e-06	1.34e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CD—breast cancer	1.37e-06	1.34e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—JUN—breast cancer	1.37e-06	1.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGF—breast cancer	1.36e-06	1.33e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CTNNB1—breast cancer	1.36e-06	1.32e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SULT1A1—breast cancer	1.35e-06	1.32e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPX4—breast cancer	1.35e-06	1.32e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—breast cancer	1.35e-06	1.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—breast cancer	1.34e-06	1.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CTNNB1—breast cancer	1.34e-06	1.31e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP3A4—breast cancer	1.33e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CA—breast cancer	1.33e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—breast cancer	1.33e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.33e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1A—breast cancer	1.32e-06	1.29e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—IDH1—breast cancer	1.32e-06	1.29e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTA1—breast cancer	1.32e-06	1.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—MAPK3—breast cancer	1.32e-06	1.29e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTEN—breast cancer	1.32e-06	1.29e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—COMT—breast cancer	1.32e-06	1.29e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP1B1—breast cancer	1.31e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—SRC—breast cancer	1.31e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTP1—breast cancer	1.31e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1A—breast cancer	1.31e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NAT2—breast cancer	1.31e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTEN—breast cancer	1.31e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	1.3e-06	1.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BRAF—breast cancer	1.3e-06	1.27e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK8—breast cancer	1.29e-06	1.26e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HMOX1—breast cancer	1.29e-06	1.26e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NOS3—breast cancer	1.29e-06	1.26e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ITPR1—breast cancer	1.29e-06	1.26e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HSP90AA1—breast cancer	1.29e-06	1.26e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CD—breast cancer	1.27e-06	1.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STAT3—breast cancer	1.26e-06	1.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1—breast cancer	1.26e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT2—breast cancer	1.26e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—breast cancer	1.26e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NCOA1—breast cancer	1.25e-06	1.22e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—breast cancer	1.25e-06	1.22e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ABCB1—breast cancer	1.24e-06	1.21e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—STK11—breast cancer	1.23e-06	1.2e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP19A1—breast cancer	1.23e-06	1.2e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HRAS—breast cancer	1.23e-06	1.2e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SRC—breast cancer	1.23e-06	1.2e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TYMS—breast cancer	1.22e-06	1.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CD—breast cancer	1.21e-06	1.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SRC—breast cancer	1.21e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK3—breast cancer	1.21e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PLA2G4A—breast cancer	1.2e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NCOR1—breast cancer	1.2e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTM1—breast cancer	1.2e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SERPINE1—breast cancer	1.2e-06	1.17e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NOS3—breast cancer	1.2e-06	1.17e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—breast cancer	1.19e-06	1.17e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CB—breast cancer	1.19e-06	1.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—KRAS—breast cancer	1.19e-06	1.16e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT3—breast cancer	1.18e-06	1.15e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—breast cancer	1.18e-06	1.15e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—breast cancer	1.18e-06	1.15e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STAT3—breast cancer	1.17e-06	1.14e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GPX1—breast cancer	1.15e-06	1.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—breast cancer	1.15e-06	1.12e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—DPYD—breast cancer	1.15e-06	1.12e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MED12—breast cancer	1.15e-06	1.12e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—COMT—breast cancer	1.15e-06	1.12e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOS3—breast cancer	1.15e-06	1.12e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTP1—breast cancer	1.14e-06	1.11e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP1A1—breast cancer	1.14e-06	1.11e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ERCC2—breast cancer	1.13e-06	1.11e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALDOA—breast cancer	1.13e-06	1.1e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK3—breast cancer	1.13e-06	1.1e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HMOX1—breast cancer	1.13e-06	1.1e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ITPR1—breast cancer	1.12e-06	1.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MAPK3—breast cancer	1.12e-06	1.09e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CB—breast cancer	1.1e-06	1.08e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—breast cancer	1.1e-06	1.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NCOA3—breast cancer	1.1e-06	1.07e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—breast cancer	1.1e-06	1.07e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—breast cancer	1.09e-06	1.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CA—breast cancer	1.09e-06	1.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC2A2—breast cancer	1.09e-06	1.06e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—breast cancer	1.09e-06	1.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MDM2—breast cancer	1.09e-06	1.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KRAS—breast cancer	1.09e-06	1.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—breast cancer	1.08e-06	1.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—breast cancer	1.08e-06	1.06e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CA—breast cancer	1.08e-06	1.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RELA—breast cancer	1.08e-06	1.05e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—breast cancer	1.07e-06	1.05e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ERBB2—breast cancer	1.07e-06	1.05e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CPT1A—breast cancer	1.07e-06	1.04e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCG2—breast cancer	1.07e-06	1.04e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTR—breast cancer	1.07e-06	1.04e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—breast cancer	1.06e-06	1.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—breast cancer	1.06e-06	1.04e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TYMS—breast cancer	1.06e-06	1.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MTOR—breast cancer	1.06e-06	1.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CB—breast cancer	1.06e-06	1.03e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PLA2G4A—breast cancer	1.05e-06	1.02e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTM1—breast cancer	1.05e-06	1.02e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NCOR1—breast cancer	1.05e-06	1.02e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HPGDS—breast cancer	1.05e-06	1.02e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HBA1—breast cancer	1.04e-06	1.01e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTEN—breast cancer	1.03e-06	1.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL8—breast cancer	1.02e-06	9.93e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KRAS—breast cancer	1.01e-06	9.91e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTT1—breast cancer	1.01e-06	9.91e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ACHE—breast cancer	1.01e-06	9.91e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HRAS—breast cancer	1.01e-06	9.86e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GPX1—breast cancer	1e-06	9.81e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KRAS—breast cancer	1e-06	9.79e-06	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CA—breast cancer	9.97e-07	9.74e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP1A1—breast cancer	9.94e-07	9.71e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1B—breast cancer	9.93e-07	9.7e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ERCC2—breast cancer	9.86e-07	9.63e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CAV1—breast cancer	9.81e-07	9.58e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—breast cancer	9.73e-07	9.5e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—breast cancer	9.71e-07	9.49e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—breast cancer	9.67e-07	9.44e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP17A1—breast cancer	9.6e-07	9.38e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTEN—breast cancer	9.53e-07	9.31e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ENO1—breast cancer	9.5e-07	9.28e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS1—breast cancer	9.5e-07	9.28e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCND1—breast cancer	9.47e-07	9.25e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JUN—breast cancer	9.45e-07	9.23e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CTNNB1—breast cancer	9.38e-07	9.16e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	9.37e-07	9.16e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CA—breast cancer	9.32e-07	9.1e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2D6—breast cancer	9.32e-07	9.1e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—breast cancer	9.27e-07	9.05e-06	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HRAS—breast cancer	9.23e-07	9.01e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CA—breast cancer	9.21e-07	8.99e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—breast cancer	9.19e-07	8.98e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1A—breast cancer	9.16e-07	8.95e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NCOA2—breast cancer	9.15e-07	8.94e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTEN—breast cancer	9.14e-07	8.93e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—breast cancer	9.02e-07	8.81e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK8—breast cancer	8.94e-07	8.73e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CG—breast cancer	8.94e-07	8.73e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—breast cancer	8.92e-07	8.71e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—FASN—breast cancer	8.87e-07	8.67e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—BCHE—breast cancer	8.83e-07	8.63e-06	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—breast cancer	8.83e-07	8.63e-06	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—breast cancer	8.83e-07	8.63e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC5A5—breast cancer	8.73e-07	8.52e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HRAS—breast cancer	8.62e-07	8.42e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CAV1—breast cancer	8.55e-07	8.35e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HRAS—breast cancer	8.52e-07	8.32e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SRC—breast cancer	8.48e-07	8.28e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC2A1—breast cancer	8.43e-07	8.23e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NQO1—breast cancer	8.43e-07	8.23e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—breast cancer	8.26e-07	8.06e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—breast cancer	8.25e-07	8.06e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT3—breast cancer	8.17e-07	7.99e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—breast cancer	8.15e-07	7.96e-06	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—breast cancer	8.15e-07	7.96e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP1B1—breast cancer	8.08e-07	7.89e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HSP90AA1—breast cancer	7.92e-07	7.74e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CD—breast cancer	7.86e-07	7.67e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK3—breast cancer	7.81e-07	7.63e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CG—breast cancer	7.79e-07	7.6e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—breast cancer	7.76e-07	7.58e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NCOA1—breast cancer	7.71e-07	7.53e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—breast cancer	7.61e-07	7.44e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—STK11—breast cancer	7.6e-07	7.42e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP19A1—breast cancer	7.6e-07	7.42e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—breast cancer	7.6e-07	7.42e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—breast cancer	7.58e-07	7.4e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—breast cancer	7.52e-07	7.35e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—breast cancer	7.43e-07	7.26e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NOS3—breast cancer	7.42e-07	7.25e-06	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CA—breast cancer	7.26e-07	7.1e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—COMT—breast cancer	7.06e-07	6.9e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTP1—breast cancer	7.03e-07	6.87e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KRAS—breast cancer	7.02e-07	6.86e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HMOX1—breast cancer	6.93e-07	6.77e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ITPR1—breast cancer	6.92e-07	6.76e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CB—breast cancer	6.85e-07	6.69e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CD—breast cancer	6.84e-07	6.69e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—breast cancer	6.78e-07	6.63e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—breast cancer	6.76e-07	6.6e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CA—breast cancer	6.73e-07	6.57e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCB1—breast cancer	6.65e-07	6.5e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TYMS—breast cancer	6.54e-07	6.38e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NOS3—breast cancer	6.46e-07	6.31e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NCOR1—breast cancer	6.46e-07	6.31e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLA2G4A—breast cancer	6.46e-07	6.31e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTM1—breast cancer	6.46e-07	6.31e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CA—breast cancer	6.45e-07	6.3e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—breast cancer	6.24e-07	6.09e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPX1—breast cancer	6.19e-07	6.04e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP1A1—breast cancer	6.12e-07	5.98e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ERCC2—breast cancer	6.07e-07	5.93e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HRAS—breast cancer	5.97e-07	5.83e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CB—breast cancer	5.97e-07	5.83e-06	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—breast cancer	5.93e-07	5.8e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTEN—breast cancer	5.92e-07	5.78e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—breast cancer	5.91e-07	5.77e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—breast cancer	5.71e-07	5.58e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—breast cancer	5.71e-07	5.58e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—breast cancer	5.49e-07	5.37e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—breast cancer	5.27e-07	5.15e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CAV1—breast cancer	5.27e-07	5.14e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTEN—breast cancer	5.15e-07	5.04e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CG—breast cancer	4.8e-07	4.69e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CD—breast cancer	4.22e-07	4.12e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CA—breast cancer	4.17e-07	4.08e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—breast cancer	4.16e-07	4.07e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NOS3—breast cancer	3.98e-07	3.89e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CB—breast cancer	3.68e-07	3.59e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—breast cancer	3.64e-07	3.56e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CA—breast cancer	3.64e-07	3.55e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—breast cancer	3.41e-07	3.33e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTEN—breast cancer	3.18e-07	3.1e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—breast cancer	2.97e-07	2.9e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CA—breast cancer	2.24e-07	2.19e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—breast cancer	1.83e-07	1.79e-06	CbGpPWpGaD
